EUVIMEDEUVIMED entdecken
Crossref

Prevalence of Metabolic Syndrome in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease

Rajat Kumar Singh, Ujjawal Priyatam, Krishna Kumar Lohani

Indian Journal of Cardio Diabetology and Metabolic Diseases · 28.10.2026 · 1 (2) · 55-57

DOI: 10.5005/ijcmd-11040-0021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Cardio Diabetology and Metabolic Diseases, online erschienen am 28.10.2026. Verfasst von Rajat Kumar Singh und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

of abdominal obesity as one factor plus at least two other components, including fasting plasma glucose or diagnosed T2DM, elevated triglyceride levels, reduced HDL cholesterol, and elevated blood pressure or use of antihypertensive therapy.4 These components represent the core metabolic abnormalities that are also integral to the development and progression of MASLD, accounting for the high prevalence of MetS in this population.According to International Diabetes Federation (IDF) criteria: IntroductIonMetabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as one of the most prevalent chronic liver conditions worldwide.The transition from the earlier terminology of nonalcoholic fatty liver disease to MASLD reflects an improved understanding of disease pathogenesis, highlighting metabolic dysfunction as the central etiological driver of hepatic steatosis.[1][2][3] This reconceptualization aligns fatty liver disease with systemic metabolic disorders rather than defining it through exclusion-based criteria.Metabolic syndrome (MetS) comprises a constellation of interrelated metabolic abnormalities, including central obesity, insulin resistance, dyslipidemia, and hypertension, which together substantially increase the risk of cardiovascular disease and type 2 diabetes mellitus (T2DM).4 MASLD is increasingly regarded as the hepatic manifestation of MetS, given the extensive overlap in epidemiology, pathophysiology, and clinical outcomes.5 The rising global burden of obesity, diabetes, and sedentary lifestyles has led to a parallel increase in both MASLD and MetS, particularly in rapidly urbanizing regions.[6][7][8] dIagnostIc crIterIa Diagnostic Criteria for MASLDMetabolic dysfunction-associated steatotic liver disease is diagnosed in individuals with evidence of hepatic steatosis detected by imaging modalities, serum biomarkers, or histological assessment in the presence of at least one metabolic risk factor such as overweight or obesity, established T2DM, hypertriglyceridemia, low high-density lipoprotein (HDL), or hypertension.2,3 This definition acknowledges the frequent coexistence of metabolic risk factors and fatty liver disease in clinical practice and allows for more accurate identification of individuals at increased cardiometabolic risk. 2 Diagnostic Criteria for MetSMetabolic syndrome is most commonly diagnosed using internationally accepted criteria that require the presence 1,

Zitieren

APA

Singh, R. K., Priyatam, U., & Lohani, K. K. (2026). Prevalence of Metabolic Syndrome in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease. Indian Journal of Cardio Diabetology and Metabolic Diseases, 1(2), 55-57. https://doi.org/10.5005/ijcmd-11040-0021

Vancouver

Singh RK, Priyatam U, Lohani KK. Prevalence of Metabolic Syndrome in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease. Indian Journal of Cardio Diabetology and Metabolic Diseases. 2026;1(2):55-57. doi:10.5005/ijcmd-11040-0021

BibTeX
@article{Singh2026,
  author = {Singh, Rajat Kumar and Priyatam, Ujjawal and Lohani, Krishna Kumar},
  title = {Prevalence of Metabolic Syndrome in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease},
  journal = {Indian Journal of Cardio Diabetology and Metabolic Diseases},
  year = {2026},
  volume = {1},
  number = {2},
  pages = {55--57},
  doi = {10.5005/ijcmd-11040-0021}
}
Kostenlos starten →